Bristol Myers Squibb strengthens oncology pipeline with USD850M Janux Therapeutics partnership

USA—Bristol Myers Squibb (BMS) is expanding its oncology portfolio through an exclusive global licensing agreement with Janux Therapeutics, marking another strategic move in the pharmaceutical giant’s dealmaking strategy.

The collaboration centers on co-developing a novel therapy designed to treat solid tumours.

Under the financial terms, BMS will pay up to USD 850 million, structured as USD 50 million in upfront and near-term payments combined with USD 800 million in regulatory, development, and milestone-based payouts.

Neither company has disclosed specific details about the therapeutic candidate at the heart of this partnership.

However, Janux revealed that the tumour-activated therapy targets a “validated solid tumour antigen” that appears commonly across multiple cancer types, potentially broadening its clinical applications.

The partnership divides responsibilities between the two companies at different stages of development.

Janux will handle the therapy’s advancement through preclinical research until the investigational new drug (IND) submission.

Once the candidate enters clinical trials, BMS takes over development and commercialisation efforts, though Janux will continue supporting the Phase I study.

Additionally, Janux stands to earn tiered royalties on global product sales if the therapy successfully reaches the market.

David Campbell, president and CEO of Janux, views the BMS collaboration as confirmation of his company’s tumour-activated platforms’ strength.

Janux has already advanced two tumour-activated T-cell engagers into clinical development using these platforms.

Among Janux’s pipeline assets is JANX007, a prostate cancer therapy candidate that targets cancer cells expressing prostate-specific membrane antigen (PSMA).

The company is currently developing this treatment for metastatic, castration-resistant prostate cancer.

Janux launched the Phase Ib ENGAGER-PSMA-01 trial (NCT05519449) in May 2025 to evaluate the therapy in this patient population.

Despite presenting what Janux considered positive interim results from this study, investors reacted negatively.

The company’s stock value plummeted more than 50 percent, dropping from USD33.99 at market close on December 1 to USD15.86 when the news broke the following day.

Since then, Janux’s share price has continued declining gradually, hovering between USD 13 and USD 14 throughout early 2026.

The announcement of the BMS licensing deal on January 22 produced only a modest uptick during the first two hours of trading rather than an immediate surge.

BMS faces significant patent challenges ahead as the pharmaceutical industry approaches one of its steepest patent cliffs in modern history.

GlobalData forecasts that by 2030, only 4 percent of global drug sales will maintain patent protection, a dramatic decline from the 12 percent rate recorded in 2022.

The company must navigate looming patent expiries for its top-selling products, Opdivo (nivolumab) and Eliquis (apixaban), which threaten future revenue streams.

Nevertheless, BMS CEO Christopher Boerner expressed confidence during the 2026 J.P. Morgan Healthcare Conference that recent high-profile deals would help offset this financial pressure.

Boerner’s strategy focuses on strengthening BMS’s core therapeutic areas: oncology, hematology, cardiovascular, neurology, and immunology.

Oncology appears particularly prioritized, with seven of the 16 deals BMS signed between 2024 and 2025 either focusing exclusively on cancer treatments or incorporating oncology elements, according to GlobalData’s Pharmaceutical Intelligence Center.

Among BMS’s notable recent transactions was its USD1.5 billion acquisition of Orbital Therapeutics, which provided access to the CAR-T specialist’s immunotherapy pipeline and further reinforced the company’s oncology ambitions.